噬菌体展示是一种高通量筛选具有特定功能的蛋白质或多肽的技术，已有多种药物借助该技术成功上市。恶性肿瘤是威胁人类健康的重要杀手；然而现有的大部分肿瘤免疫疗法都集中激活适应性免疫消除肿瘤细胞，存在疗效不尽如人意及副作用等问题。靶向CD47/SIRPα通路的免疫检查点抑制剂疗法同时激活先天性与适应性免疫，成为了抗肿瘤领域研发热点。本项目将开展靶向CD47/SIRPα通路的多肽的计算淘选研究，进一步验证淘选出的多肽的体外抑瘤活性。拟采用二代噬菌体展示技术结合多肽芯片技术，获取靶向CD47/SIRPα通路的多肽数据集及亲和力值，进而基于机器学习方法建立计算机辅助淘选平台，实现在线、快速筛选靶向该通路的CD47、SIRPα结合肽。该项目为开发靶向CD47/SIRPα信号通路的抗肿瘤药物提供一种新思路，经实验验证的CD47、SIRPα结合肽作为候选药物，具备潜在的临床应用价值。

Phage display allows high-throughput screening of proteins or peptides with specific functions, and many drugs have been successfully marketed by this technology. Malignant tumors are important killers that threaten human health. However, most of the existing cancer immunotherapy studies focus on the activation of the adaptive immune system to eliminate tumor cells, which have unsatisfactory effects and side effects. The immunological checkpoint inhibitor therapy targeting the CD47/SIRPα pathway simultaneously activates the innate and adaptive immunity systems, and has become a research hotspot in the anti-tumor field. In this study, a computational model to obtain peptides targeting the CD47/SIRPα pathway will be established. The in vitro antitumor activities of selected peptides will further to be evaluated. This project intends to use the next-generation phage display technology and peptide chip experiments to obtain peptides targeting the CD47/SIRPα pathway and the corresponding affinity data, and further establish a computer-aided panning platform based on machine learning methods. CD47- and SIRPα-binding peptides will then be efficiently acquired online. This project is expected to provide a new idea for the development of anti-tumor drugs targeting the CD47/SIRPα pathway. As candidate anti-tumor drugs, the validated CD47- and SIRPα-binding peptides will have potential clinical application value.